On October 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the third quarter of 2025 and provided a business update. The company is set to initiate the manufacturing of CYWC628 for the Phase 1/2 clinical trial in diabetic foot ulcers (DFUs). We anticipate the trial starting in the first quarter of 2026 and estimate the trial will complete in the third quarter of 2026. In addition, the company is preparing to submit Investigational New Drug (IND) applications for the treatment of psoriasis with CYPS317 and for the treatment of multiple sclerosis with CYMS101.
